China turns the tables on biotech, according to an article in Science (Volume 391, Number 6784, Page 427, January 2026).[1] Government plans since 2016, including the 13th Five-Year Plan, support the development of new chemical drugs, antibodies, vaccines, personalized medicine and stem cells.[1] The state provides financial support, licenses intellectual property from abroad and invests in laboratories, technology parks and research.[1] Chinese companies initially licensed foreign assets for the Asian market, but are gradually developing their own drugs.[1] Harmonization of regulations allows data from Chinese clinical trials to be used for approval in other countries, speeding up international collaborations.[1] The direction of licensing agreements is turning from east to west.[1] China is reaping the benefits of government investment in biomedicine at a time when the US is cutting funding to the NIH and other agencies.[1]